PE20061147A1 - Procedimiento de preparacion de compuestos antagonistas del receptor cgrp e intermediarios - Google Patents
Procedimiento de preparacion de compuestos antagonistas del receptor cgrp e intermediariosInfo
- Publication number
- PE20061147A1 PE20061147A1 PE2005001401A PE2005001401A PE20061147A1 PE 20061147 A1 PE20061147 A1 PE 20061147A1 PE 2005001401 A PE2005001401 A PE 2005001401A PE 2005001401 A PE2005001401 A PE 2005001401A PE 20061147 A1 PE20061147 A1 PE 20061147A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- formula
- xiv
- intermediaries
- procedure
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 11
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 title 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 4
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 abstract 1
- 102100038518 Calcitonin Human genes 0.000 abstract 1
- 108060001064 Calcitonin Proteins 0.000 abstract 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 230000001272 neurogenic effect Effects 0.000 abstract 1
- 102000014187 peptide receptors Human genes 0.000 abstract 1
- 108010011903 peptide receptors Proteins 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 230000024883 vasodilation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UN PROCESO PARA SINTETIZAR UN COMPUESTO DE FORMULA (XIV), (XV) O (XVI) DONDE R3 ES 7-METIL-1H-INDAZOL-5-ILO; R4 ES ALQUILO(C1-C6) O BENCILO; Y PG2 ES ETER DE METOXIMETILO, ETER DE BENCILOXIMETILO, BENCILO O TRI-ALQUILSILILO(C1-C6); QUE COMPRENDE LOS PASOS A) HIDROLIZAR UN COMPUESTO DE FORMULA (XI) DONDE PG1 ES BOC, CBZ O FMOC Y R3 ES 2,6-DIMETILANILIN-3-ILO, PARA FORMAR UN COMPUESTO DE FORMULA R4-O-C(O)-C(O)-CH2-R3 (XIII) ; B) REDUCIR EL COMPUESTO DE FORMULA (XIII) A UN COMPUESTO DE FORMULA R4-O-C(O)-C(OH)-CH2-R3 (XIV); C) PROTEGER LA PORCION HIDROXI DEL COMPUESTO (XIV) CON PG2 PARA FORMAR UN COMPUESTO DE FORMULA R4-O-C(O)-C(-O-PG2)(CH2-R3) (XV); Y D) HIDROLIZAR R4 DEL COMPUESTO (XV) PARA FORMAR UN COMPUESTO DE FORMULA (XVI). LOS COMPUESTOS OBTENIDOS POR DICHO PROCESO SON ANTAGONISTAS DE RECEPTORES DE PEPTIDO RELACIONADOS CON EL GEN DE CALCITONINA (CGRP) SIENDO UTILES EN EL TRATAMIENTO DE VASODILATACION NEUROGENICA, INFLAMACION NEUROGENICA, MIGRANA, ASMA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63315904P | 2004-12-03 | 2004-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061147A1 true PE20061147A1 (es) | 2006-10-27 |
Family
ID=36204336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001401A PE20061147A1 (es) | 2004-12-03 | 2005-12-05 | Procedimiento de preparacion de compuestos antagonistas del receptor cgrp e intermediarios |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7449586B2 (es) |
| AR (1) | AR054999A1 (es) |
| PE (1) | PE20061147A1 (es) |
| TW (1) | TW200635919A (es) |
| WO (1) | WO2006060678A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842808B2 (en) * | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
| US7220862B2 (en) * | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| PT1539766T (pt) * | 2002-06-05 | 2017-03-02 | Bristol Myers Squibb Co | Antagonistas de recetor de péptido relacionado com o gene de calcitonina |
| TW200524601A (en) | 2003-12-05 | 2005-08-01 | Bristol Myers Squibb Co | Heterocyclic anti-migraine agents |
| TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7384931B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
| US7834007B2 (en) * | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| US8067447B2 (en) * | 2006-11-01 | 2011-11-29 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| KR101608096B1 (ko) | 2008-01-23 | 2016-03-31 | 브리스톨-마이어스 스큅 컴퍼니 | 4-피리디논 화합물 및 암을 위한 그의 용도 |
| CN105037210A (zh) * | 2015-05-27 | 2015-11-11 | 江苏大学 | 一种α,β-脱氢-α-氨基酸的合成方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997009046A1 (en) | 1995-09-05 | 1997-03-13 | Smithkline Beecham Corporation | Compounds and methods |
| AU4261697A (en) | 1996-09-09 | 1998-03-26 | Smithkline Beecham Corporation | Compounds and methods |
| ATE266673T1 (de) * | 1996-09-10 | 2004-05-15 | Boehringer Ingelheim Pharma | Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| WO1998056779A1 (en) | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists |
| US20030069231A1 (en) * | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| CA2327695A1 (en) | 1998-04-08 | 1999-10-21 | Takeda Chemical Industries, Ltd. | Amine compounds, their production and their use as somatostatin receptor antagonists or agonists |
| AU6211499A (en) | 1998-09-30 | 2000-04-17 | Merck & Co., Inc. | Benzimidazolinyl piperidines as cgrp ligands |
| US6313097B1 (en) * | 1999-03-02 | 2001-11-06 | Boehringer Ingelheim Pharma Kg | Antagonists of calcitonin gene-related peptide |
| DE19911039A1 (de) | 1999-03-12 | 2000-09-14 | Boehringer Ingelheim Pharma | Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US6521609B1 (en) * | 1999-08-10 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes |
| EP1227090A4 (en) | 1999-10-07 | 2002-11-20 | Tadeka Chemical Ind Ltd | AMINE DERIVATIVES |
| DE19952147A1 (de) * | 1999-10-29 | 2001-05-03 | Boehringer Ingelheim Pharma | Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19952146A1 (de) | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19963868A1 (de) | 1999-12-30 | 2001-07-12 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| JP2004518613A (ja) | 2000-08-01 | 2004-06-24 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | イミダゾリル誘導体 |
| US20030181462A1 (en) * | 2001-08-17 | 2003-09-25 | Boehringer Ingelheim Pharma Kg | Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine |
| US7193070B2 (en) | 2001-09-27 | 2007-03-20 | Merck & Co., Inc. | Isolated DNA molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods |
| US6900317B2 (en) * | 2002-02-19 | 2005-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them |
| DE10206770A1 (de) | 2002-02-19 | 2003-08-28 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096 |
| US20040014679A1 (en) * | 2002-02-20 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof |
| DE10211770A1 (de) | 2002-03-14 | 2003-10-02 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US7026312B2 (en) * | 2002-03-14 | 2006-04-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
| US7220862B2 (en) * | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| PT1539766T (pt) * | 2002-06-05 | 2017-03-02 | Bristol Myers Squibb Co | Antagonistas de recetor de péptido relacionado com o gene de calcitonina |
| US20040076587A1 (en) * | 2002-06-19 | 2004-04-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical composition for intranasal administration containing a CGRP antagonist |
| DE10250080A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE10250082A1 (de) * | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE10300973A1 (de) * | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| ATE535514T1 (de) | 2003-03-14 | 2011-12-15 | Merck Sharp & Dohme | Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten |
| JP4673295B2 (ja) | 2003-03-14 | 2011-04-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 単環式アニリドスピロヒダントインcgrp受容体拮抗物質 |
| WO2004082678A1 (en) | 2003-03-14 | 2004-09-30 | Merck & Co. Inc. | Aryl spirohydantoin cgrp receptor antagonists |
| AU2004226018B2 (en) | 2003-03-14 | 2009-08-27 | Merck Sharp & Dohme Corp. | Benzodiazepine spirohydantoin CGRP receptor antagonists |
| ATE394400T1 (de) | 2003-03-14 | 2008-05-15 | Merck & Co Inc | Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten |
| US20040248816A1 (en) * | 2003-04-01 | 2004-12-09 | Boehringer Ingelheim International Gmbh | Treatment of migraine |
| ATE466860T1 (de) | 2003-04-15 | 2010-05-15 | Merck Sharp & Dohme | Cgrp-rezeptorantagonisten |
| JO2355B1 (en) * | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| CA2529196A1 (en) | 2003-06-26 | 2005-02-17 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
| CN1812982B (zh) | 2003-06-26 | 2010-10-27 | 默沙东公司 | 苯并二氮杂*cgrp受体拮抗剂 |
| DE10329881A1 (de) * | 2003-07-02 | 2005-01-20 | Sick Ag | Lichtgitter |
| US20050032783A1 (en) * | 2003-07-07 | 2005-02-10 | Boehringer Ingelheim International Gmbh | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients |
| EP1646611A1 (en) | 2003-07-15 | 2006-04-19 | Merck & Co., Inc. | Hydroxypyridine cgrp receptor antagonists |
| US20050065094A1 (en) * | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
| TW200524601A (en) | 2003-12-05 | 2005-08-01 | Bristol Myers Squibb Co | Heterocyclic anti-migraine agents |
| CA2549330A1 (en) | 2003-12-05 | 2005-07-21 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| WO2005072308A2 (en) | 2004-01-29 | 2005-08-11 | Merck & Co., Inc. | Cgrp receptor antagonists |
| US20050192230A1 (en) * | 2004-02-12 | 2005-09-01 | Boehringer Ingelheim International Gambh | Process for preparing 1- [N²-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine |
| WO2005084672A1 (de) | 2004-03-03 | 2005-09-15 | Boehringer Ingelheim International Gmbh | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| DE102004015723A1 (de) * | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| DE102004018795A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE102004018796A1 (de) | 2004-04-15 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE102004018794A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7279471B2 (en) * | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| JP2007533685A (ja) | 2004-04-20 | 2007-11-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 偏頭痛を治療するためのセロトニン再吸収阻害剤と組合わせたcgrpアンタゴニストの使用 |
| US20050233980A1 (en) * | 2004-04-20 | 2005-10-20 | Boehringer Ingelheim International Gmbh | CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine |
| DE102004019492A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7696195B2 (en) * | 2004-04-22 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| DE102004027912A1 (de) * | 2004-06-09 | 2005-12-29 | Grünenthal GmbH | Substituierte Cyclopenten-Verbindungen |
| US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
-
2005
- 2005-12-01 US US11/291,670 patent/US7449586B2/en active Active
- 2005-12-02 WO PCT/US2005/043670 patent/WO2006060678A2/en not_active Ceased
- 2005-12-02 TW TW094142586A patent/TW200635919A/zh unknown
- 2005-12-02 AR ARP050105057A patent/AR054999A1/es not_active Application Discontinuation
- 2005-12-05 PE PE2005001401A patent/PE20061147A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200635919A (en) | 2006-10-16 |
| WO2006060678A3 (en) | 2006-07-20 |
| US7449586B2 (en) | 2008-11-11 |
| US20060122250A1 (en) | 2006-06-08 |
| WO2006060678A2 (en) | 2006-06-08 |
| AR054999A1 (es) | 2007-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20061147A1 (es) | Procedimiento de preparacion de compuestos antagonistas del receptor cgrp e intermediarios | |
| CY1110243T1 (el) | Ανταγωνιστες npyy5 | |
| PE20221628A1 (es) | Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos | |
| TW363064B (en) | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | |
| BRPI0817096A8 (pt) | Análogo de tiazolidinodiona e composição farmacêutica que o compreende | |
| PE20020381A1 (es) | COMPUESTOS DE PIRROLO[2,3-d]PIRIMIDINA COMO INHIBIDORES DE LA PROTEINA QUINASA | |
| UY28014A1 (es) | Compuestos quimicos | |
| PL211243B6 (pl) | Kompozycja farmaceutyczna antagonisty receptora tachykininy | |
| PE20040937A1 (es) | Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4) | |
| BRPI0309534B8 (pt) | derivados de triazol como antagonistas do receptor de taquicinina, seu uso, e composição farmacêutica | |
| CO6400144A2 (es) | Derivados aminoéster de alcaloides y composición medicinal de los mismos | |
| EA201270550A1 (ru) | Процесс получения соединений для применения в качестве ингибиторов sglt2 | |
| MX340572B (es) | Proceso para la fabricacion de compuestos farmaceuticamente activos. | |
| LV5794B4 (lv) | Nonapeptidi ar bombezina antagonistu ipasibam | |
| ATE340795T1 (de) | Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten | |
| ECSP109958A (es) | Derivados de pirimidina 934 | |
| BR0309028A (pt) | Compostos policìclicos como antagonistas potentes de alfa2-adrenoceptores | |
| DE602005019316D1 (en) | Aromatische etherderivate als thrombin-hemmer | |
| MX2023005892A (es) | Compuestos ciclicos novedosos, metodo para su preparacion y el uso de dichos compuestos ciclicos en preparaciones cosmeticas. | |
| NO20084698L (no) | Metode for fremstilling av indazolyl-ureaer som inhiberer vanilloidreseptor subtype 1(VR1) | |
| PE20091359A1 (es) | Proceso de preparacion de compuestos organicos intermediarios de inhibidores de renina | |
| PE20090515A1 (es) | Nuevo procedimiento de preparacion | |
| ATE384066T1 (de) | Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren | |
| ATE502936T1 (de) | 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten | |
| DE602004029383D1 (de) | Isten und antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |